GU Cancers 2019 | Enzalutamide after docetaxel for mCRPC: evaluation by the Italian Named Patient Program

In this moment, in Italy, it is possible to use enzalutamide in M0 CRPC patients. But I think this is a pretty changing condition which produces great effects following treatment. The main in terms of castration-resistant prostate cancer patients because I think that all conditions where new androgen receptor targeting agents such as

In this moment, in Italy, it is possible to use enzalutamide in M0 CRPC patients. But I think this is a pretty changing condition which produces great effects following treatment. The main in terms of castration-resistant prostate cancer patients because I think that all conditions where new androgen receptor targeting agents such as enzalutamide or also apalutamide in the next future. It changes our approach in the castration-resistant prostate cancer patients because the main problem is the possibility of cross-resistance between the two different new hormonal agents.

In other terms, I don’t know, in this moment if the abiraterone works after enzalutamide given in an M0 patients when the patients develop the castration-resistant disease. At the same time, we don’t know what is the rate of activity of docetaxel or cabazitaxel when these patients became castration-resistant. Because I think all changes we made in terms of therapeutic approach in castration-sensitive disease, these are related to a change in the biology of the disease. And at this moment we don’t know what happened when the disease became castration-resistant.